Biotech Values

[DewDiligence]

[NVS] also have a variety of patents on other isoforms/polymorphs/crstalline formulations that they will try to use to defend against generics beyond the base patent expiry.

Almost all drugs have such patents, and the statement above on defending IP against generics is boilerplate stuff that every company says in response to questions from analysts.

The clue to what NVS actually expects vis-à-vis generic Gleevec is that NVS has guided analysts not to include large Gleevec sales in the analysts’ post-2015 models.